Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Standard Chem & Pharm Co. Ltd. (1720.TW)
Tainan City, TW
Standard Chem & Pharm Co. Ltd. (SCP) is a Taiwanese enterprise specializing in the development, manufacturing, and commercialization of a broad spectrum of pharmaceutical products, nutritional supplements, and Active Pharmaceutical Ingredients (APIs). The company's diverse offerings include medications targeting various therapeutic areas, such as the circulatory, digestive, and respiratory systems. Their portfolio also features antihistamines, central nervous system (CNS) agents, metabolism-regulating drugs, anti-microbial treatments, and topical preparations for skin and mucous membrane conditions. Beyond finished drug products, SCP provides APIs for both human and veterinary applications, as well as various pharmaceutical excipients. Founded in 1967, Standard Chem & Pharm Co. Ltd. maintains its corporate headquarters in Tainan City, Taiwan.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.97% | -0.33% | -3.17% | +0.16% | -1.61% | +3.57% | +3.04% | -11.59% | +58.03% | +86.26% | +319.82% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2025-08 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+3.4% Q1'26: +0.7% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+5.1% Q1'26: +19.3% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+19.4% Q1'26: +27.4% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+19.4% ★ Q1'26: +20.8% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+13.7% ★ Q1'26: +13.3% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+35.2% Q1'26: +28.6% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×0.74× ★ Q1'26: 0.97× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
3.32B
est: 3.43B (-3.1%)
|
3.67B
est: 3.43B (+7.2%)
|
3.85B
est: 3.52B (+9.4%)
|
3.57B
est: 3.83B (-6.7%)
|
3.94B
est: 3.94B (0.0%)
|
4.31B
est: 4.23B (+1.9%)
|
4.60B
est: 4.60B (+0.0%)
|
5.85B
est: 5.13B (+14.0%)
|
6.24B
est: 6.56B (-4.9%)
|
6.79B
est: 6.80B (-0.2%)
|
7.02B
est: 7.13B (-1.5%)
|
| EBITDA |
666.30M
est: 921.86M (-27.7%)
|
688.04M
est: 921.86M (-25.4%)
|
756.38M
est: 946.25M (-20.1%)
|
727.80M
est: 1.03B (-29.3%)
|
808.65M
est: 1.06B (-23.7%)
|
1.01B
est: 1.14B (-11.1%)
|
1.25B
est: 1.24B (+0.8%)
|
1.66B
est: 1.38B (+19.9%)
|
1.58B
est: 1.76B (-10.5%)
|
2.06B
est: 1.86B (+10.7%)
|
1.80B
est: 1.95B (-7.8%)
|
| EBIT |
383.49M
est: 740.84M (-48.2%)
|
418.14M
est: 740.84M (-43.6%)
|
541.48M
est: 760.44M (-28.8%)
|
526.47M
est: 827.64M (-36.4%)
|
596.28M
est: 851.68M (-30.0%)
|
780.50M
est: 913.95M (-14.6%)
|
1.02B
est: 995.47M (+2.6%)
|
1.42B
est: 1.11B (+27.8%)
|
1.26B
est: 1.42B (-11.2%)
|
1.65B
est: 1.49B (+11.0%)
|
1.36B
est: 1.56B (-12.7%)
|
| Net Income |
347.89M
est: 363.17M (-4.2%)
|
340.22M
est: 363.17M (-6.3%)
|
363.29M
est: 440.09M (-17.5%)
|
374.36M
est: 359.59M (+4.1%)
|
376.48M
est: 372.11M (+1.2%)
|
524.17M
est: 466.93M (+12.3%)
|
706.73M
est: 699.50M (+1.0%)
|
1.15B
est: 651.20M (+77.2%)
|
834.89M
est: 962.48M (-13.3%)
|
880.50M
est: 1.20B (-26.9%)
|
927.66M
est: 1.26B (-26.3%)
|
| SGA |
872.61M
est: 691.12M (+26.3%)
|
917.01M
est: 691.12M (+32.7%)
|
967.89M
est: 709.41M (+36.4%)
|
920.91M
est: 772.10M (+19.3%)
|
973.56M
est: 794.53M (+22.5%)
|
992.48M
est: 852.62M (+16.4%)
|
948.47M
est: 928.66M (+2.1%)
|
1.10B
est: 1.04B (+6.2%)
|
1.21B
est: 1.32B (-8.6%)
|
1.29B
est: 1.31B (-1.2%)
|
1.29B
est: 1.37B (-6.0%)
|
| EPS |
1.95
est: 2.03 (-3.9%)
|
1.90
est: 2.03 (-6.4%)
|
2.03
est: 2.46 (-17.5%)
|
2.09
est: 2.01 (+4.0%)
|
2.11
est: 2.08 (+1.4%)
|
2.93
est: 2.61 (+12.3%)
|
3.96
est: 3.91 (+1.3%)
|
6.46
est: 3.64 (+77.5%)
|
4.67
est: 5.38 (-13.2%)
|
4.94
est: 4.98 (-0.8%)
|
5.19
est: 5.20 (-0.2%)
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-08 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-07 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-06 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-05 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-04 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-30 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-29 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-28 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-27 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-24 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-23 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-22 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-21 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-20 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-17 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-16 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | State Street SPDR S&P Emerging Markets Small Cap ETF EWX | 0.02% | 120.6K | 0.65% |
| 2 | Avantis Emerging Markets ex-China Equity ETF AVXC | 0.01% | 24.0K | 0.33% |
| 3 | Dimensional - Emerging Markets Value ETF DFEV | 0.00% | 70.3K | 0.46% |
| 4 | Avantis Emerging Markets Small Cap Equity ETF AVEE | 0.00% | 4.0K | 0.42% |
| 5 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 265.2K | 0.39% |
| 6 | Dimensional Emerging Markets Sustainability Core 1 ETF DFSE | 0.00% | 12.1K | 0.44% |
| 7 | Dimensional - Emerging Core Equity Market ETF DFAE | 0.00% | 148.4K | 0.29% |
| 8 | Dimensional World ex U.S. Core Equity 2 ETF DFAX | 0.00% | 120.7K | 0.28% |
| 9 | Avantis Emerging Markets Equity ETF AVEM | 0.00% | 31.8K | 0.33% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Chin Wen Chang | Financial Officer, Accounting Officer & Corporate Governance Officer | — | — |
| Tzu-Ting Fan | Chairman of the Board & GM | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 1720.TW
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
